Restoration of fibroblast growth factor receptor2 suppresses growth and tumorigenicity of malignant human prostaste carcinoma PC-3 cells

Prostate

Volumn 61, Issue 3, 2004, Pages 236-242

  Yasumoto, Hiroaki ^a   Matsubara, Akio ^a   Mutaguchi, Kazuaki ^a   Usui, Tsuguru ^a   McKeehan, Wallace L ^b  

^a HIROSHIMA UNIVERSITY   (Japan)

^b TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

FRS2; Gene therapy; MAP kinase; Stromal epithelial interactions; Tumor suppression; Tyrosine kinases

Indexed keywords

FIBROBLAST GROWTH FACTOR 10; FIBROBLAST GROWTH FACTOR RECEPTOR 2; KERATINOCYTE GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P44;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOGENICITY; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; EPITHELIUM CELL; GENE THERAPY; HOMEOSTASIS; HUMAN; HUMAN CELL; IMMUNOCHEMISTRY; MALE; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROSTATE; PROSTATE CARCINOMA; PROTEIN EXPRESSION;

APOPTOSIS; CELL COMMUNICATION; CELL DIFFERENTIATION; CELL DIVISION; CELL LINE, TUMOR; EPITHELIAL CELLS; GENE EXPRESSION; GENE THERAPY; HUMANS; MALE; MITOGEN-ACTIVATED PROTEIN KINASES; PROSTATIC NEOPLASMS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; RECEPTORS, FIBROBLAST GROWTH FACTOR; STROMAL CELLS; TRANSFECTION;

EID: 5344273996     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.20093     Document Type: Article

References (31)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26.
2. Nakata S, Takahashi H, Ohtake N, Takei T, Yamanaka H. Trends and characteristics in prostate cancer mortality in Japan. Int J Urol 2000;7:254-257.
3. Kirby RS, Christmas TJ, Drawer MK. Management of metastatic disease. In: Hamilton L, editor. Prostate cancer. London: Mosby, 1996. pp 129-141.
4. Scardino PT. The prevention of prostate cancer - The dilemma continues. N Engl J Med 2003;349:297-299.
5. Cunha GR, Hayward SW, Wang YZ, Ricke WA. Role of the stromal microenvironment in carcinogenesis of the prostate. Int J Cancer 2003;107:1-10.
6. Yan G, Fukabori Y, Nikolaropoulos S, Wang F, McKeehan WL. Heparin-binding keratinocyte growth factor is a candidate stromal-to-epithelial-cell andromedin. Mol Endocrinol 1992;6: 2123-2128.
7. Cunha GR. Epithelio-mesenchymal interactions in primordial gland structures which become responsive to androgenic stimulation. Anat Rec 1972;172:179-195.
8. Cunha GR, Fujii H, Neubauer BL, Shannon JM, Sawyer L, Reese BA. Epithelial-mesenchymal interactions in prostatic development. I. Morphological observations of prostatic induction by urogenital sinus mesenchyme in epithelium of the adult rodent urinary bladder. J Cell Biol 1983;96:1662-1670.
9. Lu W, Luo Y, Kan M, McKeehan WL. Fibroblast growth factor-10. A second candidate stromal to epithelial cell andromedin in prostate. J Biol Chem 1999;274:12827-12834.
10. Sugimura Y, Foster BA, Hom YK, Lipschutz JH, Rubin JS, Finch PW, Aaronson SA, Hayashi N, Kawamura J, Cunha GR. Keratinocyte growth factor (KGF) can replace testosterone in the ductal branching morphogenesis of the rat ventral prostate. Int J Dev Biol 1996;40:941-951.
11. Nakano K, Fukabori Y, Itoh N, Lu W, Kan M, McKeehan WL, Yamanaka H. Androgen-stimulated human prostate epithelial growth mediated by stromal-derived fibroblast growth factor-10. Endocr J 1999;46:405-413.
12. Yan G, Fukabori Y, McBride G, Nikolaropoulos S, McKeehan WL. Exon switching and activation of stromal and embryonic fibroblast growth factor (FGF)-FGF receptor genes in prostate epithelial cells accompany stromal independence and malignancy. Mol Cell Biol 1993;13:4513-4522.
13. Naimi B, Latil A, Fournier G, Mangin P, Cussenot O, Berthon P. Down-regulation of (IIIb) and (IIIc) isoforms of fibroblast growth factor receptor 2 (FGFR2) is associated with malignant progression in human prostate. Prostate 2002;52:245-252.
14. Carstens RP, Eaton JV, Krigman HR, Walther PJ, Garcia-Blanco MA. Alternative splicing of fibroblast growth factor receptor 2 (FGF-R2) in human prostate cancer. Oncogene 1997;15:3059-3065.
15. Werner S, Duan DS, de Vries C, Peters KG, Johnson DE, Williams LT. Differential splicing in the extracellular region of fibroblast growth factor receptor 1 generates receptor variants with different ligand-binding specificities. Mol Cell Biol 1992;12:82-88.
16. Kan M, Uematsu F, Wu X, Wang F. Directional specificity of prostate stromal to epithelial cell communication via FGF7/ FGFR2 is set by cell- and FGFR2 isoform-specific heparan sulfate. In Vitro Cell Dev Biol Anim 2001;37:575-577.
17. Takahashi H. Studies on the expression of fibroblast growth factors and fibroblast growth factor receptors in human prostate cancer. Nippon Hinyokika Gakkai Zasshi 1998;89:836-845.
18. Kwabi-Addo B, Ropiquet F, Giri D, Ittmann M. Alternative splicing of fibroblast growth factor receptors in human prostate cancer. Prostate 2001;46:163-172.
19. Giri D, Ropiquet F, Ittmann M. Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer. Clin Cancer Res 1999;5:1063-1071.
20. Feng S, Wang F, Matsubara A, Kan M, McKeehan WL. Fibroblast growth factor receptor 2 limits and receptor 1 accelerates tumorigenicity of prostate epithelial cells. Cancer Res 1997;57: 5369-5378.
21. Matsubara A, Kan M, Feng S, McKeehan WL. Inhibition of growth of malignant rat prostate tumor cells by restoration of fibroblast growth factor receptor 2. Cancer Res 1998;58:1509-1514.
22. Zhang Y, Wang H, Toratani S, Sato JD, Kan M, McKeehan WL, Okamoto T. Growth inhibition by keratinocyte growth factor receptor of human salivary adenocarcinoma cells through induction of differentiation and apoptosis. Proc Natl Acad Sci USA 2001;98:11336-11340.
23. Ricol D, Cappellen D, El Marjou A, Gil-Diez-de-Medina S, Girault JM, Yoshida T, Ferry G, Tucker G, Poupon MF, Chopin D, Thiery JP, Radvanyi F. Tumour suppressive properties of fibroblast growth factor receptor 2-IIIb in human bladder cancer. Oncogene 1999;18:7234-7243.
24. van Sande M, Van Camp K. Lactoferrin in human prostate tissue. Urol Res 1981;9:241-244.
25. Barresi G, Tuccari G. Lactoferrin in benign hypertrophy and carcinomas of the prostatic gland. Virchows Arch A Pathol Anat Histopathol 1984;403:59-66.
26. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 1979;17:16-23.
27. Kozolowski JM, McEwan R, Keer H, Sensibar J, Sherwood ER, Lee C, Grayhack JT, Albini A, Martin GR. Prostate cancer and the invasive phenotype: Application of new in vivo and in vitro approaches. In: Fidler IJ, Nicholson G, editors. Tumor progression and metastasis. New York: Alan R. Liss, Inc., 1988. pp 189-231.
28. Kaighn ME, Lechner JF, Narayan KS, Jones LW. Prostate carcinoma: Tissue culture cell lines. Natl Cancer Inst Monogr 1978;49:17-21.
29. van Bokhoven A, Varella-Garcia M, Korch C, Johannes WU, Smith EE, Miller HL, Nordeen SK, Miller GJ, Lucia MS. Molecular characterization of human prostate carcinoma cell lines. Prostate 2003;57:205-225.
30. Lebedeva IV, Sarkar D, Su ZZ, Kitada S, Dent P, Stein CA, Reed JC, Fisher PB. Bcl-2 and Bcl-x(L) differentially protect human prostate cancer cells from induction of apoptosis by melanoma differentiation associated gene-7, mda-7/IL-24. Oncogene 2003;22:8758-8773.
31. Wang F, McKeehan K, Yu C, Ittmann M, McKeehan WL. Chronic activity of ectopic type 1 fibroblast growth factor receptor tyrosine kinase in prostate epithelium results in hyperplasia accompanied by intraepithelial neoplasia. Prostate 2004;58:1-12.